Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOMNART: Sleep Health in HIV on Dolutegravir vs Doravirine ART
NCT07673965Phase 4Not yet recruiting
- Sponsor
- University of the Witwatersrand
- Start
- Oct 2026
- Primary completion
- Aug 2027
01
Overview
Phase 4, randomised, open-label trial of doravirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of the Witwatersrand. Primary endpoint: RU-SATED total score at 12 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07673965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07673965.